PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS
Crwe World,
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
PharmAust announces positive Phase 1 MEND Study Top-Line Results in MND / ALS PR Newswire PERTH, Australia, Feb.
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
Highlights: PERTH, Australia Study Design The Phase 1 MEND Study was a multicentre, open label study comprising a 24-hour…
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
Highlights: Monepantel displays a superior safety, tolerability to the leading FDA approved drug Relyvrio® Preliminary efficacy…
J Neurol. 2015 Apr 11; Authors: Elamin M, Bede P, Montuschi A, Pender N, Chio A, Hardiman O PubMed: 25860344 Submit Comment